 | |
| Clinical data | |
|---|---|
|
Pregnancy category |
|
|
Routes of administration | Injection into pleural space or abdomen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.222.897 |
| Chemical and physical data | |
| Formula | C23H31N3O4S2 |
| Molar mass | 477.64 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Batimastat ( mnemonic: batty-mustard) ( INN/ USAN, codenamed BB-94) is a drug that was invented by Laurie Hines of British Biotech (now Vernalis). It is an anti metastatic drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides. Dan Lednicer wrote about this compound in book #6 of his organic drug synthesis series.[ citation needed]
Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis. [1]
It is well-known that other methods of administration include transdermal (skin lotion) as well as rectal suppositories.
References
- ^ Rothenberg ML, Nelson AR, Hande KR (1999). "New drugs on the horizon: matrix metalloproteinase inhibitors". Stem Cells. 17 (4): 237–40. doi: 10.1002/stem.170237. PMID 10437989.
This article incorporates
public domain material from
Dictionary of Cancer Terms.
U.S. National Cancer Institute.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
|
Pregnancy category |
|
|
Routes of administration | Injection into pleural space or abdomen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.222.897 |
| Chemical and physical data | |
| Formula | C23H31N3O4S2 |
| Molar mass | 477.64 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Batimastat ( mnemonic: batty-mustard) ( INN/ USAN, codenamed BB-94) is a drug that was invented by Laurie Hines of British Biotech (now Vernalis). It is an anti metastatic drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor (MMPI) by mimicking natural MMPI peptides. Dan Lednicer wrote about this compound in book #6 of his organic drug synthesis series.[ citation needed]
Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar MMPI marimastat), and injection into the peritoneum caused peritonitis. [1]
It is well-known that other methods of administration include transdermal (skin lotion) as well as rectal suppositories.
References
- ^ Rothenberg ML, Nelson AR, Hande KR (1999). "New drugs on the horizon: matrix metalloproteinase inhibitors". Stem Cells. 17 (4): 237–40. doi: 10.1002/stem.170237. PMID 10437989.
This article incorporates
public domain material from
Dictionary of Cancer Terms.
U.S. National Cancer Institute.
|
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |